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When we consider that creatinine
and uric acid, for example, are excreted
in concentrations of about 15 and 5
mmoLfL, we can already observe posi-
tive biases caused by these interfer-
encesat a sample:reagent volume ratio
of 1:5 (1). However, this ratio does not
yet permit measurement of microalbu-
minuria. Thus, the interferingreac-
tions of urinary components with
bromphenol blue preclude use of this
dye-binding method for determination
of microalbuminuria in native urine
samples. These interferences by non-
protein constituents of urinewould ex-
plain why the Microalbutest (Miles
__________________________ Labs., Ames Div.) showed falsely posi-
0 0 50 100 150 200 tive results (2).
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Fig. 1. Effect of creatinine (U), uric acid (A),
urea (x), and NaCI (0) on determination of
albuminwithbromphenolblue
All pointsare meanvaluesoffivefolddeterminations.
Concentrationsindicatedarefinalooncentrationsin
the reaction mbcture
munonephelometry) have been recom-
mended for thispurpose.
In order to use the simple and inex-
pensive dye-binding method with
bromphenol blue (1), we tried to im-
prove the analytical sensitivity by in-
creasing the ratio of urinary sample to
reagent volume. To detect microalbu-
minuria (20 mgfL) with sufficient sen-
sitivity, we found, in model experi-
ments with solutions of human albu-
min, that this ratio had to be about 1:2.
Then we added known amounts of hu-
man albumin (Impfstoffwerke, Dessau,
G.D.R.) to various urine specimensand
made recovery experiments. Large dif.
ferences were observed between mea-
sured and calculated values as com-
pared with values obtained byimmuno-
diffusion (VLC-Partigen-Albumin;
Behning AG, Marburg/Lahn, F.R.G.).
These differences depended both on the
sample:reagent volume ratio and on
the individual urine investigated. To
evaluate interfering reactions of non-
protein components of urine with
bromphenol blue, we added 0.5 mL of a
100 mg/L albumin solution to 0.5 mL of
urea, uric acid, creatinine, or NaC1
solutions of different concentrations.
Then we mixed in 0.1 mL of brom-
phenol blue reagent (2 mmol of brom-
phenol blue and 8.25 g of Brij35 per
liter of glycine buffer, 1.1 moliL, pH
3.0) and, 30 s later, measured the ab-
sorbance at 610 nm in a spectropho-
tometer with a 10-mm lightpath (Mod-
el DU-8; Beckman Instruments, Ful-
lerton, CA). Interference by creatinine,
uric acid, and NaCl with bromphenol
blue is clearly demonstrated in Figure
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More on Oligoclonal Bands and
Diagnosis of Multiple Sclerosis
To the Editor:
We would like to report our contribu-
tion regarding the “dilemma” raised by
Stanley et al. (1) and recently dis-
cussedby Tate and Campbell (2), con-
cerning the relationship between the
diagnosis of multiple sclerosis (MS)
and the presence of oligoclonal bands
that are unique to the cerebrospinal
fluid (CSF).
We considered isoelectric focusing
(IEF) patternsfor CSF and serum from
94 patients, who met the criteria of
McDonald and Halliday (3) for a clini-
cal diagnosis of definite MS. The speci-
mens, collected between January 1985
and July 1988, were all treated in the
same way. Essentially, we standard-
ized the concentration of IgG in CSF
(by using Amicon CS 15 concentrators)
and in serum (by diluting the sera with
distilled water) so we could apply a
constant amount, 20 g, of IgG to the
gel surfaceby use of pieces of filter
paper. For the IEF we used thin-layer
polyacrylamide gel (Ampholine PAG-
plate, pH range 3.5-9.5; LKB), stain-
ing with Coomassie Brilliant Blue.
On the basis of the IEF findings, the
94 patients could be divided into three
groups. Group I, comprising 66 pa-
tients (70%), had oligoclonal bands,
numbering three or more, only in their
CSF. Group II, 20 patients (21%), had
some bands common to both CSF and
serum but also some unique to CSF.
Group ifi, eight patients (9%), had no
oligoclonal bands in either CSF or in
serum. Thus Groups I and II, with at
least three or more bands in CSF only,
represented 91% of all these patients.
One patient affected by both MS and,
in association, Sjogren’s syndrome
(specific antibodies to SSAJRo present
in his serum) had multiple oligoclonal
bands in CSF and also three that ap-
peared in IEF patternsfor both CSF
and serum. This might resultfrom the
combination of two different immuno-
logical mechanisms, functioning in the
systemic and intrathecal compart-
ments, respectively.
We also found bands unique to CSF,
together with some others paired in
CSF and in serum, in 78% (18 of 23)
cases of MDS with central nervous sys-
tem involvement.
In a group of other neurological dis-
eases (e.g., extrapyramidal degenera-
tive disease, neurosyphilis, chronic
myelopathy of unknown cause, poly-
neuropathy, Guillain-Barr#{233}syndrome,
and dementia) we found some cases
that showed, on IEF, patternsof bands
identical in CSF and serum and, occa-
sionally (<5%), bands unique to CSF.
Moreover, our preliminary data con-
cerning patients with acute unilateral
optic neuritis indicate that those pa-
tients who have oligoclonal banding in
CSF have an increased risk for future
development of MS. This underlines
the importance of detecting oligoclonal
fractions in CSF from cases of suspect-
ed MS, as an aid in early diagnosis of
the disease.
In any case, in agreement with Tate
and Campbell (2), we never found any
patient with clinically definite MS who
had an identical banding pattern in
both CSF and serum.
References
1. Stanley MJ, Schmierer DM, Millingen
KS, Yen PT. Oligoclonal bands are found in
electrophoretograms of serum of patients
withmultiple sclerosis[Letter]. Clin Chem
1986;32:709.
2. Tate J, Campbell B. Must CSF oligo-
clonal bands be unique to cerebrospinal
fluid and absent from serum to support the
Table 1. Monoclonal Gammopathies during the Follow-up of Eight
Asymptomatlc HIV-Seroposltlve Subjects
Patlnts
A B C 0 E F G H
(II)’ (II) (II) (II) (III) (II) (II) (III)
Semiannual
test no.
1 - - 9 2 -
(204)L) (622) (400) (350) (213)
2 5 9 3 -
(298) ND (510) (370) (350)
3 6 3.5 7
ND (311) ND (580) (332)
4 5 6 11 3.7 15+7c
(210) (412) (300) (530) (240)
5 - 4 3+10c
(220) (240) ND (680)
6 - 11
(410) (380) (340)
ND = notdone.
CDC stageatstartof andthroughoutstudy Is listed in parentheses.b Results shown areconcentration
(mg/L)orabsence (-) ofMG, with number ofCD4lymphocytesper microliter listed parenthetically.CA
second MG (lgG kappa) wasdetectedatthistesting.
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Assessing Metabolic Acidosis
To the Editor:
Kost et al. (1) recently reported the
case of a 10-year-old boy with diabetic
ketoacidosis in whom there was a dis-
crepancy between the value for plasma
bicarbonate calculated by the blood-
gas analyzer (with use of the Hender-
son-Hasselbaich equation) and the
value for TCO2 measured in the labo-
ratory. They were able to calculate
that at the height of the acidosis the
value for pK1’ was 5.49, differing
markedly from the 6.1 used by the
blood-gasanalyzer. We are entirely in
agreement with them that the most
nearly accurate estimation of the bi-
carbonate concentration in plasma is
obtained by directly measuring the
TCO2 in arterial blood. However, we can
not agreewith their statement that the
assumption of constant plC1’ is no long-
er tenable when therapeutic decisions
are necessary for acid-base manage-
ment. We maintain thatthe character-
ization of an acid-base disturbance
provided by the calculated value for
plasma bicarbonate, as measured in a
blood-gas analyzer, is quite accurate
enough for clinicalpurposes.We have
shown this to be the case in the neo-
nate (2), and we believe that in the
casereported by Kost et al. the value
for calculated bicarbonateserved its
purpose in demonstrating that there
was a profound metabolic acidosis. The
use of intravenous bicarbonate in the
treatment of diabetic ketoacidosis re-
mains controversial (3), but we think
that most clinicians who use intrave-
nous bicarbonate in these circum-
stances would prefer to titrate the bi-
carbonate infusion against a series of
arterial blood-gas analyses, rather
than expect to calculate a “once-and-
for-all” dose aimed at a particular de-
sired plasma bicarbonate concentra-
tion. The clinical situation is by its
very nature unpredictable because of
the interplay of the disease state and
the therapy with insulin. Because the
greatestdeviations in pK1’ are likely
to coincide with the extremes of disor-
dered metabolism, the value for plas-
ma bicarbonate calculated by the
blood-gas analyzer should become
more nearly accurateas the patient
improves-and this was indeed what
happened in the case reported by Kost
etal.
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Follow-up of Monoclonal
Gammopathies In Asymptomatlc
HIV-lnfected Subjects
To the Editor:
Monoclonal gammopathies (MG)
have beendescribedin .kmS patients (1,
2) and, more recently, in asymptomatic
subjects infected with human immuno-
deficiency virus (H1V) (3-5). Because
the prognostic value of finding MG in
these subjectsis not known, we fol-
lowed up these asymptomatic subjects,
to determine whether their outcome
differed from that of seropositive sub-
jectswithout MG. Both groups of sub-
jectswere under observation in our
unit.
Eight HJV-seropositive subjects (pos-
itive by EUSA, with confirmation by
Western blot) with MG (sixIgG kappa,
two IgG lambda) were seen semiannu-
ally over a mean period of 25.5 months
(range 18-30). The subjects, ages 23-
45 y (mean 33) were four homosexual
men, two transfusion recipients, one
female partnerof a high-risk subject,
and one subject without known risk
factors. All subjectswere asymptomat-
ic for AIDS during the study period
(stage H or ifi according to the criteria
of the U.S. Centers for Disease Con-
trol). MG was identifiedby immunofix-
ation and quantified by electrophoresis
on cellulose acetate. Semestrialobser-
vations included physical examination
(lymph nodes) and laboratory tests for
CD4 and CD8 lymphocyte count; p24
antigen; anti-core (p24 and p1’?) anti-
bodies; erythrocyte sedimentation rate;
concentrations of IgG, IgA, and 1gM in
serum (quantified by laser nephelome-
try); and serum protein electrophoresis
to detect monoclonal bands. No subject
received antiviral therapy before or
during the study period. Table 1 gives,
for each visit, the concentration of MG
and the CD4 lymphocyte count of the
eight subjects over the study period.
We observedthe appearance of MG in
five subjects (they did not have MG at
the start of the study and were retro-
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